adecatumumab

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 477242160

| type = mab

| mab_type = mab

| source = u

| target = EpCAM

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 503605-66-1

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 000705ZASD

| ATC_prefix = none

| ATC_suffix =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| C=6552 | H=10080 | N=1740 | O=2052 | S=46

}}

Adecatumumab (MT201) is a recombinant human IgG1 monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen.{{cite web | title = Adecatumumab - Amgen/Merck Serono | url = http://adisinsight.springer.com/drugs/800013072 | work = Adis Insight | publisher = Springer Nature Switzerland AG }}

Adecatumumab has been used in clinical studies of treatment in colorectal, prostate{{cite journal | vauthors = Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, Locher M, Prang N, Baeuerle PA, Leo E | display-authors = 6 | title = A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients | journal = European Journal of Cancer | volume = 42 | issue = 15 | pages = 2530–8 | date = October 2006 | pmid = 16930989 | doi = 10.1016/j.ejca.2006.05.029 }} and breast cancers.{{cite journal | vauthors = Prang N, Preithner S, Brischwein K, Göster P, Wöppel A, Müller J, Steiger C, Peters M, Baeuerle PA, da Silva AJ | display-authors = 6 | title = Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines | journal = British Journal of Cancer | volume = 92 | issue = 2 | pages = 342–9 | date = January 2005 | pmid = 15655555 | pmc = 2361858 | doi = 10.1038/sj.bjc.6602310 }} Phase II results were published in 2010.{{cite journal | vauthors = Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, Schmidt M, Rüttinger D, Schuler M, Reinhardt C, Awada A | display-authors = 6 | title = An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer | journal = Annals of Oncology | volume = 21 | issue = 2 | pages = 275–82 | date = February 2010 | pmid = 19633042 | doi = 10.1093/annonc/mdp314 | doi-access = free }}